Global Health Ltd (Medanta) (NSE: MEDANTA, BSE: 543654) is a Gurugram, Haryana-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹38,422 Cr, it ranks #243 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 46 in Hospitals and Healthcare Centers. At ₹1,453.00 (as of 16 Nov 2026), the share price is 5.9% below its 52-week high of ₹1,544.00 and 52.0% above its 52-week low of ₹956.00. The share price is up 16.2% over one year and up 3.1% over three months.
| Current Price | ₹1,453.00 |
|---|---|
| Market Cap | ₹38,422 Cr |
| NSE Symbol | MEDANTA |
| BSE Code | 543654 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 69.7 |
| Return on Equity | 15.03% |
| Return on Assets | 8.22% |
| 52-Week Range | ₹956.00 – ₹1,544.00 |
| 1-Year Price Change | +16.2% |
| 3-Month Price Change | +3.1% |
| Beta (1Y) | 0.17 |
| Dividend Yield | 0.03% |
| Headquarters | Gurugram, Haryana |
| Website | www.medanta.org |
| Revenue | ₹1,469 Cr |
|---|---|
| Net Profit | ₹219 Cr |
| Net Margin | 14.9% |
| EPS (Basic) | ₹8.21 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Global Health Ltd (Medanta) reported revenue of ₹1,469 Cr in Q2 FY27, up 33.6% from ₹1,099 Cr in Q2 FY26 and up 12.7% from ₹1,304 Cr in Q1 FY27. It posted a net profit of ₹219 Cr for the quarter, against a net profit of ₹158 Cr in Q2 FY26 (up 38.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹931 Cr (Q4 FY25) to ₹1,469 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,469 Cr | ₹219 Cr | 14.9% |
| Q1 FY27 | ₹1,304 Cr | ₹157 Cr | 12.1% |
| Q4 FY26 | ₹1,159 Cr | ₹142 Cr | 12.2% |
| Q3 FY26 | ₹1,121 Cr | ₹95 Cr | 8.5% |
| Q2 FY26 | ₹1,099 Cr | ₹158 Cr | 14.4% |
| Q1 FY26 | ₹1,031 Cr | ₹159 Cr | 15.4% |
| Q4 FY25 | ₹931 Cr | ₹101 Cr | 10.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 33.00% of Global Health Ltd (Medanta)'s shares as of Sept 2026, against 33.01% in Sept 2025 (−0.01 percentage points). Delivery averaged 54.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and ot
1. The Healthcare Services-This segment offers healthcare services. 2. 0-0 3. 0-0 4. 0-0
1. The Healthcare Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Dr. Agarwal's Health Care Limited | ₹17,568 Cr | 131.9 | 8.31% | ₹655 Cr | +9.3% |
Listed by market capitalisation. Ratios are shown for context only.
Global Health Ltd (Medanta) is trading at ₹1,453.00, with a market capitalisation of ₹38,422 Cr.
Global Health Ltd (Medanta) operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Global Health Ltd (Medanta) has a P/E of 69.7 and a return on equity of 15.03%.
Global Health Ltd (Medanta) is listed on the NSE under the symbol MEDANTA and on the BSE under the scrip code 543654.
Global Health Ltd (Medanta)'s share price is up 16.2% over one year and up 3.1% over three months. Its 52-week range is ₹956.00 to ₹1,544.00.
In Q2 FY27, Global Health Ltd (Medanta) reported revenue of ₹1,469 Cr and net profit of ₹219 Cr, with basic EPS of ₹8.21 (consolidated, parsed from the company's exchange filing).
Global Health Ltd (Medanta) reported revenue of ₹1,469 Cr in Q2 FY27, up 33.6% from ₹1,099 Cr in Q2 FY26 and up 12.7% from ₹1,304 Cr in Q1 FY27.
Promoters held 33.00% of Global Health Ltd (Medanta)'s shares as of Sept 2026, against 33.01% in Sept 2025 (−0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.